Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort

Autor: Laurent Guilleminault, Lise Rosencher, A. Proust, Arnaud Bourdin, Clairelyne Dupin, S. Fry, Drifa Belhadi, Cécile Chenivesse, Patrick Berger, Frédéric de Blay, Alain Didier, Anne‐Sophie Gamez, Camille Couffignal, Philippe Bonniaud, Gilles Garcia, Camille Taillé, Pierre-Olivier Girodet, Chantal Raherison, Christophe Leroyer, Geneviève Le Bourdellès, Guillaume Mahay

Publikováno v: Clinical and Experimental Allergy
Clinical and Experimental Allergy, 2020, 50 (7), pp.789-798. ⟨10.1111/cea.13614⟩
Clinical and Experimental Allergy, Wiley, 2020, 50 (7), pp.789-798. ⟨10.1111/cea.13614⟩

International audience; Background: Dupilumab is a monoclonal anti‐IL‐4Rα antibody developed for the treatment of severe asthma (SA). An early access programme for dupilumab was opened in France in SA patients experiencing unacceptable steroids

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc72298191e997663d15a304a8e3d89e
https://doi.org/10.1111/cea.13614

A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

Autor: John Wrangle, Ticiana Leal, Gilles Robinet, Neal Ready, David Maag, Jyoti Malhotra, Melissa Lynne Johnson, Satwant Lally, Petros Nikolinakos, Jyoti D. Patel, Daniel Morgensztern, Benjamin Besse, Vincent Blot, Giuseppe Curigliano, Ricardo Valenzuela, Laurent Greillier, Jonathan M. Lehman

Publikováno v: Journal of Thoracic Oncology
Journal of Thoracic Oncology, 2021, 16 (9), pp.1559-1569. ⟨10.1016/j.jtho.2021.02.022⟩

Introduction This open-label, phase 1–2 study evaluated the safety and efficacy of rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, plus immune checkpoint inhibitors nivolumab plus or minus ipilimumab in previously treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7c2323534cecd409bf8ef57951bfa24
https://doi.org/10.1016/j.jtho.2021.02.022

From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement

Autor: Coënon, Loïs, Villalba, Martin

Publikováno v: Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2022, 13, pp.913215. ⟨10.3389/fimmu.2022.913215⟩

International audience; Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclona

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c3b85a834634f937684ad7eebcdc0a5
https://doi.org/10.3389/fimmu.2022.913215

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

Autor: Lorena Donnici, Rino Rappuoli, Ian A. Wilson, Matteo Conti, Hugo Mouquet, Hejun Liu, Raffaele De Francesco, Claudia Sala, Ida Paciello, Gabriel Ozorowski, Timothée Bruel, Giulia Piccini, Cyril Planchais, Jonathan L. Torres, Olivier Schwartz, Jeffrey Copps, Piero Pileri, Noemi Manganaro, Elisa Pantano, Emanuele Montomoli, Delphine Planas, Andrew B. Ward, Emanuele Andreano

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 (20), pp.e2120976119. ⟨10.1073/pnas.2120976119⟩

As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for highly potent monoclonal antibodies (mAbs) that are resistant against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) variants of concern (VoCs). H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b8a15b231e75ae887ea462311512d6
https://doi.org/10.1073/pnas.2120976119

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis

Autor: Alexandra Garcia, Emilie Dugast, Sita Shah, Jérémy Morille, Christine Lebrun-Frenay, Eric Thouvenot, Jérôme De Sèze, Emmanuelle Le Page, Sandra Vukusic, Aude Maurousset, Eric Berger, Olivier Casez, Pierre Labauge, Aurélie Ruet, Catarina Raposo, Fabien Bakdache, Régine Buffels, Fabienne Le Frère, Arnaud Nicot, Sandrine Wiertlewski, Pierre-Antoine Gourraud, Laureline Berthelot, David Laplaud

Publikováno v: Neurology Neuroimmunology & Neuroinflammation
Neurology Neuroimmunology & Neuroinflammation, 2023, 10 (3), pp.e200091. ⟨10.1212/NXI.0000000000200091⟩

Background and ObjectivesOcrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc1d798b10a68a099da6e914a7f048c8
https://doi.org/10.1212/nxi.0000000000200091